Literature DB >> 26260701

Brachytherapy: state-of-the-art radiotherapy in prostate cancer.

Michael W T Chao1, Peter Grimm2, John Yaxley3, Raj Jagavkar4, Michael Ng5, Nathan Lawrentschuk6,7.   

Abstract

Entities:  

Keywords:  brachytherapy; cost-effectiveness; high-dose rate; low-dose rate; prostate cancer; quality of life

Mesh：

Year:  2015        PMID： 26260701     DOI： 10.1111/bju.13252

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  7 in total

1.  Evaluation of pelvic floor muscle strength before and after robotic-assisted radical prostatectomy and early outcomes on urinary continence.

Authors:  Lauren Manley; Luke Gibson; Nathan Papa; Bhawanie Koonj Beharry; Liana Johnson; Nathan Lawrentschuk; Damien M Bolton
Journal:  J Robot Surg       Date:  2016-05-09

2.  [Nonhealing ulcer after hemorrhoid treatment].

Authors:  J Jongen; R Buchholz; H-G Peleikis; N Nürnberg; V Kahlke
Journal:  Urologe A       Date:  2017-03       Impact factor: 0.639

3.  125I brachytherapy in younger prostate cancer patients : Outcomes in low- and intermediate-risk disease.

Authors:  Isabelle Kindts; Karin Stellamans; Ignace Billiet; Hans Pottel; Antoon Lambrecht
Journal:  Strahlenther Onkol       Date:  2017-05-09       Impact factor: 3.621

Review 4.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

Review 5.  Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Emile N van Lin; Joep G H van Roermund; Philippe Lambin
Journal:  Biomed Res Int       Date:  2016-12-28       Impact factor: 3.411

6.  Quality of Health Information on the Internet for Prostate Cancer.

Authors:  Dwayne T S Chang; Robert Abouassaly; Nathan Lawrentschuk
Journal:  Adv Urol       Date:  2018-12-04

7.  Cost-consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer.

Authors:  Ivar S Jensen; Joanne Hathway; Philip Cyr; David Gauden; Peter Gardiner
Journal:  J Mark Access Health Policy       Date:  2020-04-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.